Atherosclerosis Market is predicted to reach USD 62.420 billion at a CAGR of 3.50% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Atherosclerosis Market”.

The atherosclerosis market is estimated to register a CAGR of 3.50% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global atherosclerosis market - F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Allergan (Ireland), AstraZeneca (U.K.), Boehringer Ingelheim International GmbH. (Germany), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Bayer AG (Germany), and Dr. Reddy's Laboratories Ltd. (India).

Market Highlights

The global atherosclerosis market is accounted to register a CAGR of 3.50% during the forecast period and is estimated to reach USD 62.420 billion by 2032.

The market is expected to grow more quickly due to the increasing frequency of cardiovascular disorders worldwide. Growing healthcare costs are a major element driving the atherosclerosis market's growth rate as they contribute to infrastructural improvements. Additionally, by boosting funding, a number of government groups hope to strengthen the healthcare infrastructure, which would further impact market dynamics. The market for atherosclerosis will also grow as a result of growing awareness-raising campaigns by public and private entities.

Access full report @ https://www.marketresearchfuture.com/reports/atherosclerosis-market-20668

Segment Analysis

The global atherosclerosis market has been segmented into stage, diagnosis, treatment, and end-user.

On the basis of stage, the market is segmented into Endothelial Damage and Immune Response, Fatty Streak, Plaque Growth, and Plaque Rupture The endothelial damage and immune response segment was attributed to holding the largest market share in 2022 propelled by factors such as the rising prevalence of risk factors like diabetes and hypertension, advancements in diagnostic technology, and expanding public knowledge of the significance of cardiovascular health. Research and development in targeted therapeutics for endothelial dysfunction is another factor contributing to the growth of this market sector.

Based on diagnosis, the global atherosclerosis market has been segmented into Ankle-brachial Index (ABI), Doppler Ultrasound, Echocardiogram, Electrocardiogram (ECG), Blood Tests, and Others. The electrocardiogram (ECG) segment was expected to hold the largest market share in 2022 due to increased knowledge, advances in electrocardiography technology, and a rise in the prevalence of atherosclerotic illnesses. The market is expanding due to two additional factors: the aging population and the addition of ECG to telemedicine.

Based on treatment, the global atherosclerosis market has been segmented into Medication and Surgery. The surgery segment was expected to hold the largest market share in 2022 attributed to advances in minimally invasive surgery, an increase in the incidence of atherosclerosis, and rising patient awareness. The surgical market is expanding due to many causes such as aging populations, the desire for better treatments, and technological improvements.

Based on end-user, the global atherosclerosis market has been segmented into Hospitals, Specialty Clinics, Homecare, and Others. The hospitals segment was expected to hold the largest market share in 2022 ascribed to elements such the growing incidence of atherosclerosis, improvements in medical technology for detection and therapy, growing public awareness, and an aging population that results in an increase in the number of patients needing hospital care.

Regional Analysis

The global atherosclerosis market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe atherosclerosis market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The atherosclerosis market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World atherosclerosis market comprises of Middle East, Africa, and Latin America.

The largest market share for atherosclerosis was maintained by the North American regional sector. Some of the main factors contributing to the market's significant share are the prevalence of atherosclerosis and cardiovascular diseases, the presence of large players, and the stability of the healthcare system. It is also expected that supportive government initiatives and an increase in research collaborations will drive market growth.

Moreover, the Europe market has been persistently growing over the forecast period. Numerous variables, such as the presence of significant players, the high prevalence of cardiovascular diseases (CVD) and atherosclerosis, and a sophisticated healthcare system, are responsible for its considerable market share.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period due to the region's increasing proportion of senior citizens and increased disposable income. Furthermore, the market is expected to grow at a faster rate in this sector as a result of expanding government initiatives and the expansion of healthcare infrastructure.

Furthermore, the rest of the world's atherosclerosis market is divided into the Middle East, Africa, and Latin America. The aging population, changing lifestyles, rising rates of cardiovascular disease, and better healthcare facilities are all contributing factors to the growth of the atherosclerosis market in rest of world. Growing public awareness, improvements in medical technology, and government initiatives all support the market's growth.

Key Findings of the Study

• The global atherosclerosis market is expected to reach USD 62.420 billion by 2032, at a CAGR of 3.50% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the region's increasing proportion of senior citizens and increased disposable income.


• Based on diagnosis, the Electrocardiogram (ECG) segment was attributed to holding the largest market in 2022, with an approximate market share of 37%.


• Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Allergan (Ireland), AstraZeneca (U.K.), Boehringer Ingelheim International GmbH. (Germany), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Bayer AG (Germany), and Dr. Reddy's Laboratories Ltd. (India).